Developer docs
API playgroundTry for free, no card

Search company profiles

Umoja Biopharma

Full company profile

uuid00004pn

Namestring
Umoja Biopharma
Legal namestring
Umoja Biopharma, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Umoja Biopharma is a clinical-stage biotechnology company founded in 2019 and headquartered in Seattle, Washington, developing in vivo CAR T cell therapies intended to address unmet needs in B-cell hematologic malignancies, multiple myeloma, Non-Hodgkin Lymphoma, autoimmune disease, and solid tumors. The company's core technology is the VivoVec platform, a surface-engineered lentiviral vector delivery system using Multi-Domain Fusion (MDF) surface engineering and cocal fusion glycoprotein pseudotyping to generate CAR T cells directly inside the patient's body via a single infusion, eliminating ex vivo cell manufacturing and lymphodepleting chemotherapy. VivoVec is complemented by three integrated platforms: RACR (Rapamycin-Activated Cytokine Receptor) for in vivo cell expansion and persistence, TumorTag bispecific small molecule adaptors for tagging tumor cells for destruction by universal TagCAR T cells, and Engineered iPSCs for allogeneic off-the-shelf cell therapy manufacturing. Umoja is the only in vivo CAR T cell company with in-house CGMP manufacturing, operating the 146,000 sq ft CLIMB facility in Louisville, Colorado (opened October 2023, fully operational 2024), with additional R&D and process development in Boulder.

Umoja's pipeline comprises five programs: UB-VV111 (CD19 in vivo CAR T, FDA IND cleared 2024, Fast Track Designation September 30, 2025; Phase 1 NCT06528301, partnered with AbbVie under an exclusive option), UB-VV400/410 (CD22, Phase 1 NCT06743503, partnered with IASO Biotherapeutics for NHL and autoimmune indications), UB-VV300/310 (CD20, IND-enabling preclinical), UB-VV500 (industry-first dual-targeted BCMA x GPRC5D in vivo CAR T for multiple myeloma, preclinical data at ASGCT May 13, 2026, Phase 1 planned by end of 2026), and UB-TT170 (TumorTag targeting folate receptors in osteosarcoma, Phase 1 ENLIGHTen trial at Seattle Children's). The company is pre-revenue and clinical-stage, with no approved products. Operations are funded by equity financings — a $210M Series B in June 2021 (co-led by SoftBank Vision Fund 2 and Cormorant Asset Management) and a $100M Series C in January 2025 (co-led by Double Point Ventures and DCVC Bio) — supplemented by licensing and co-development capital from AbbVie (CD19 option), Nona Biosciences (expanded November 2025), and IASO Biotherapeutics (CD22 in-license). The commercial model is built around out-licensing, milestone payments, and eventual royalties via strategic pharma partners, with future distribution anticipated through specialty oncology and cell therapy centers following the established CAR T standard of care.

Short descriptiontext

Umoja Biopharma is a clinical-stage biotechnology company developing in vivo CAR T cell therapies using its proprietary VivoVec lentiviral platform to generate CAR T cells directly inside patients, targeting B-cell malignancies, multiple myeloma, and solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vivo CAR T therapy, cancer immunotherapy, lentiviral vector platform, cell therapy manufacturing, engineered T cell therapies
Industry3 codes
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
In Vivo CAR T Cell Therapy
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Out-licensing option / milestone payments
TypeLicensing Royalties
Description

AbbVie retains an exclusive option to license Umoja's CD19-directed in vivo CAR T cell therapy candidates, including UB-VV111. Future revenue would come from option exercise fees, milestone payments, and royalties upon commercialization.

umoja-biopharma.com
2Co-development milestone payments
TypeLicensing Royalties
Description

Expanded collaboration with Nona Biosciences to develop multiple in vivo CAR-T products includes financial milestones for Nona Biosciences; Umoja will handle further development and commercialization.

biospace.com
3Pre-revenue clinical-stage operations
TypeSubscription Recurring
Description

Company is clinical-stage and has not yet generated product revenue; operations are funded by equity financings (Series B $210M in 2021, Series C $100M in 2025) and strategic partner capital.

umoja-biopharma.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1VivoVec
Description

Umoja's flagship proprietary in vivo gene delivery platform that enables the in vivo generation of CAR T cells within the patient's body using a lentiviral vector delivery system.

umoja-biopharma.com
+2 more records
Core offering1 text field

Umoja Biopharma develops in vivo CAR T cell therapies using its proprietary VivoVec platform, a surface-engineered lentiviral vector delivery system that generates chimeric antigen receptor (CAR) T cells directly inside the patient's body via a single infusion. The approach eliminates the weeks-to-months-long ex vivo cell manufacturing process and the need for lymphodepleting chemotherapy, with complementary platforms (RACR, TumorTag, Engineered iPSCs) supporting in vivo cell expansion, tumor targeting, and allogeneic manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • UB-VV111 was the first in vivo CAR T cell therapy to receive FDA IND clearance in 2024 and FDA Fast Track Designation in September 2025.
+4 more records
Product overview1 text field

Umoja Biopharma is a clinical-stage biotechnology company pioneering in vivo CAR T cell therapies through an integrated platform-plus-modules architecture. The core technology platform, VivoVec, is a surface-engineered lentiviral vector delivery system that generates CAR T cells directly inside the patient's body, bypassing the complexity of ex vivo manufacturing. VivoVec is complemented by two synergistic modular platforms: the RACR (Rapamycin-Activated Cytokine Receptor) platform, which enhances survival and expansion of in vivo-engineered cells (and also drives ShRED differentiation of iPSCs), and the TumorTag platform, a portfolio of bispecific small molecule adaptors that selectively label tumor cells for recognition by universal TagCAR T cells. Together these three platforms power Umoja's pipeline of clinical and preclinical product candidates: UB-VV111 (CD19 in vivo CAR T, FDA Fast Track Designation), UB-VV400/410 (CD22 in vivo CAR T, in-licensed from IASO Biotherapeutics), UB-VV300/310 (CD20 in vivo CAR T), UB-VV500 (BCMA x GPRC5D dual-targeted in vivo CAR T for multiple myeloma), and UB-TT170 (TumorTag targeting folate receptors for osteosarcoma). The Engineered iPSCs platform provides an allogeneic, off-the-shelf manufacturing route. All in vivo CAR T candidates are manufactured at Umoja's company-owned CLIMB facility in Louisville, Colorado, the only in-house lentiviral vector manufacturing capability among in vivo CAR T cell companies. Umoja's CD19 program (UB-VV111) is out-licensed to AbbVie under an exclusive option, while UB-VV400/410 is in-licensed from IASO Biotherapeutics.

Product and service10 records
1VivoVec Platform
CategoryCore Technology Platform
Description

Surface-engineered lentiviral vector delivery platform that generates CAR T cells directly within the patient's body via a single infusion, bypassing ex vivo cell production. Features Multi-Domain Fusion (MDF) surface engineering and cocal fusion glycoprotein pseudotyping, and is modular to deliver any CAR payload against multiple surface targets. Licensed for CD19 candidates to AbbVie under exclusive option.

2RACR (Rapamycin-Activated Cytokine Receptor) Platform
CategoryCore Technology Platform
Description

Synthetic cytokine receptor system combined with VivoVec to provide enhanced survival and expansion to in vivo-generated immune cells. Activated by rapamycin (an FDA-approved drug) to provide a proliferative signal that can replace lymphodepleting chemotherapy; also enables Synthetic Receptor Enabled Differentiation (ShRED) of iPSCs.

3TumorTag Platform
CategoryCore Technology Platform
Description

Portfolio of bispecific small molecule adaptors that selectively bind tumor or tumor stromal cells and label them with fluorescein (or other tags), marking them for destruction by universal TagCAR T cells. Cocktails of TumorTags enable labeling of multiple targets to address antigen escape and tumor heterogeneity in solid tumors.

4Engineered iPSCs Platform
CategoryCore Technology Platform
Description

Induces pluripotent stem cells engineered with RACR and universal TagCAR to produce off-the-shelf, allogeneic immune effector cells (RACR-iCIL) with unlimited expansion capacity, genomic consistency, and protection against host-versus-graft rejection.

5UB-VV111
CategoryClinical-Stage Product Candidate
Description

Investigational off-the-shelf in vivo CAR T cell therapy targeting CD19 for hematologic malignancies, including relapsed/refractory Large B-cell Lymphoma and Chronic Lymphocytic Leukemia. Generates CD19-directed CAR T cells in vivo using VivoVec platform, eliminating ex vivo manufacturing and lymphodepletion. First in vivo CAR T to receive FDA IND clearance.

6UB-VV400/410
CategoryClinical-Stage Product Candidate
Description

In vivo CAR T cell therapy program targeting CD22 for the treatment of Non-Hodgkin Lymphoma and autoimmune diseases, built on the VivoVec platform. In-licensed from IASO Biotherapeutics. Phase 1 trial ongoing (NCT06743503).

7UB-VV300/310
CategoryPreclinical Product Candidate
Description

Preclinical in vivo CAR T cell therapy program targeting CD20, currently in IND-enabling stage of preclinical development. Built on the VivoVec platform.

8UB-VV500
CategoryPreclinical Product Candidate
Description

Umoja's dual-targeted BCMA x GPRC5D in vivo CAR T cell therapy program for the treatment of multiple myeloma. Described as the industry's first combination BCMA x GPRC5D in vivo CAR T cell therapy for multiple myeloma, addressing antigen escape after single-target BCMA therapy.

9UB-TT170
CategoryClinical-Stage Product Candidate
Description

Proprietary TumorTag small molecule that selectively binds to folate receptors (FR) on tumor cells, labels them with fluorescein, and marks them for destruction by anti-fluorescein CAR T cells. Initial indication in osteosarcoma (up to 80% of osteosarcoma tumor samples show FR expression). Being evaluated in the Phase 1 ENLIGHTen clinical trial at Seattle Children's.

10CLIMB (Colorado Laboratory & Innovative Manufacturing Building)
CategoryManufacturing Facility / Infrastructure
Description

Company-owned 146,000 square-foot lentiviral vector development and manufacturing facility in Louisville, Colorado, co-located with R&D labs. Umoja is the only in vivo CAR T cell therapy company with in-house manufacturing capacity, using a suspension-based process with both transient transfection and stable producer cell line technologies to produce VivoVec-based drug products.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Expanded collaboration to develop multiple in vivo CAR-T products using combined platforms. The agreement includes financial milestones for Nona Biosciences; Umoja will handle further development and commercialization of the resulting therapies.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-01-01
Description

AbbVie holds an exclusive option to license Umoja's CD19-directed in vivo CAR T cell therapy candidates, including UB-VV111 (NCT06528301). AbbVie's existing $1.4 billion option deal is widely noted by industry analysts as a key strategic consideration for any future acquisition of Umoja.

Strategic tierMajorTypeImplementation/ SI/ Consulting PartnerAnnounced on2022-05-03
Description

Phase 1 ENLIGHTen trial partnership for UB-TT170 TumorTag with Seattle Children's Therapeutics providing anti-fluorescein CAR T cells manufactured in their Cure Factory GMP facility. Seattle Children's also founded the underlying scientific work supporting Umoja.

4IASO Biotherapeutics
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

In-licensing partner for Umoja's CD22-directed program (UB-VV400/410) for Non-Hodgkin Lymphoma and autoimmune indications, currently in Phase 1 (NCT06743503).

umoja-biopharma.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Capstan Therapeutics is a clinical-stage biotech developing in vivo CAR T cell therapies using lipid nanoparticle (LNP) delivery of mRNA. Directly comparable to Umoja as an in vivo CAR T peer pursuing the same core thesis of generating CAR T cells inside the patient without ex vivo manufacturing.

TypeDirect peer
Description

Interius was a clinical-stage in vivo CAR T company using viral vector delivery to generate CAR T cells in vivo. Acquired by Gilead/Kite for $350M, validating the in vivo CAR T category and providing a comparable benchmark for Umoja's platform approach.

TypeDirect peer
Description

Kelonia is an in vivo CAR T company using lentiviral vector delivery. Acquired by Eli Lilly for approximately $7B, representing the largest in vivo CAR T exit to date and a key comparable for valuing Umoja's platform.

TypeEmerging player
Description

Ensoma is a genomics medicine company developing in vivo gene editing and cell therapy using engineered viral vectors. Comparable as an in vivo engineered cell therapy peer, though with a broader gene editing focus rather than purely CAR T.

TypeDirect peer
Description

Caribou Biosciences is a clinical-stage cell therapy company developing allogeneic CAR T cell therapies using CRISPR gene editing. Comparable to Umoja as a cell therapy platform company pursuing off-the-shelf CAR T approaches, though using ex vivo rather than in vivo manufacturing.

TypeDirect peer
Description

Allogene Therapeutics is a clinical-stage cell therapy company developing allogeneic (off-the-shelf) CAR T cell therapies for hematologic malignancies and solid tumors. Comparable to Umoja as an off-the-shelf CAR T peer addressing the same patient access barriers, though using ex vivo allogeneic manufacturing.

TypeDirect peer
Description

CRISPR Therapeutics is a clinical-stage gene editing company developing CRISPR/Cas9-edited allogeneic CAR T cell therapies. Comparable to Umoja as a next-generation engineered cell therapy peer with active clinical CAR T programs in hematologic malignancies.

8Bristol Myers Squibb
TypeBroad incumbent
Description

Bristol Myers Squibb markets Breyanzi (liso-cel) and Abecma (ide-cel) CAR T cell therapies. Comparable to Umoja as a broad incumbent offering commercial CAR T products in the same B-cell and multiple myeloma indications Umoja is pursuing with UB-VV111 and UB-VV500.

TypeBroad incumbent
Description

Gilead's Kite Pharma division markets Yescarta and Tecartus CAR T cell therapies for hematologic malignancies. Comparable to Umoja as a broad incumbent with active in vivo CAR T investment (Interius acquisition $350M) overlapping with Umoja's pipeline indications.

TypeBroad incumbent
Description

Novartis markets Kymriah, the first FDA-approved CAR T cell therapy, and has active cell therapy pipeline investment. Comparable to Umoja as a broad incumbent in CAR T cell therapy commercialization, particularly relevant given AbbVie's option on Umoja's CD19 program (Kymriah's primary indication).

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Umoja Biopharma

In Vivo CAR T Cell Therapyumoja-biopharma.com

Umoja Biopharma is a clinical-stage biotechnology company developing in vivo CAR T cell therapies using its proprietary VivoVec lentiviral platform to generate CAR T cells directly inside patients, targeting B-cell malignancies, multiple myeloma, and solid tumors.

What Umoja Biopharma does

Umoja Biopharma is a clinical-stage biotechnology company founded in 2019 and headquartered in Seattle, Washington, developing in vivo CAR T cell therapies intended to address unmet needs in B-cell hematologic malignancies, multiple myeloma, Non-Hodgkin Lymphoma, autoimmune disease, and solid tumors. The company's core technology is the VivoVec platform, a surface-engineered lentiviral vector delivery system using Multi-Domain Fusion (MDF) surface engineering and cocal fusion glycoprotein pseudotyping to generate CAR T cells directly inside the patient's body via a single infusion, eliminating ex vivo cell manufacturing and lymphodepleting chemotherapy. VivoVec is complemented by three integrated platforms: RACR (Rapamycin-Activated Cytokine Receptor) for in vivo cell expansion and persistence, TumorTag bispecific small molecule adaptors for tagging tumor cells for destruction by universal TagCAR T cells, and Engineered iPSCs for allogeneic off-the-shelf cell therapy manufacturing. Umoja is the only in vivo CAR T cell company with in-house CGMP manufacturing, operating the 146,000 sq ft CLIMB facility in Louisville, Colorado (opened October 2023, fully operational 2024), with additional R&D and process development in Boulder.

Umoja's pipeline comprises five programs: UB-VV111 (CD19 in vivo CAR T, FDA IND cleared 2024, Fast Track Designation September 30, 2025; Phase 1 NCT06528301, partnered with AbbVie under an exclusive option), UB-VV400/410 (CD22, Phase 1 NCT06743503, partnered with IASO Biotherapeutics for NHL and autoimmune indications), UB-VV300/310 (CD20, IND-enabling preclinical), UB-VV500 (industry-first dual-targeted BCMA x GPRC5D in vivo CAR T for multiple myeloma, preclinical data at ASGCT May 13, 2026, Phase 1 planned by end of 2026), and UB-TT170 (TumorTag targeting folate receptors in osteosarcoma, Phase 1 ENLIGHTen trial at Seattle Children's). The company is pre-revenue and clinical-stage, with no approved products. Operations are funded by equity financings — a $210M Series B in June 2021 (co-led by SoftBank Vision Fund 2 and Cormorant Asset Management) and a $100M Series C in January 2025 (co-led by Double Point Ventures and DCVC Bio) — supplemented by licensing and co-development capital from AbbVie (CD19 option), Nona Biosciences (expanded November 2025), and IASO Biotherapeutics (CD22 in-license). The commercial model is built around out-licensing, milestone payments, and eventual royalties via strategic pharma partners, with future distribution anticipated through specialty oncology and cell therapy centers following the established CAR T standard of care.

Umoja Biopharma firmographics

Firmographics
Name
Umoja Biopharma
Legal name
Umoja Biopharma, Inc.
Website
https://umoja-biopharma.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
251–500 employees
Short description
Umoja Biopharma is a clinical-stage biotechnology company developing in vivo CAR T cell therapies using its proprietary VivoVec lentiviral platform to generate CAR T cells directly inside patients, targeting B-cell malignancies, multiple myeloma, and solid tumors.
Ownership category
akta.pro rank

Umoja Biopharma industry classification

Industry
Product category
In Vivo CAR T Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • In vivo CAR T therapy
  • Cancer immunotherapy
  • Lentiviral vector platform
  • Cell therapy manufacturing
  • Engineered T cell therapies

Where Umoja Biopharma is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Umoja Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Out-licensing option / milestone payments: AbbVie retains an exclusive option to license Umoja's CD19-directed in vivo CAR T cell therapy candidates, including UB-VV111. Future revenue would come from option exercise fees, milestone payments, and royalties upon commercialization.
  2. Co-development milestone payments: Expanded collaboration with Nona Biosciences to develop multiple in vivo CAR-T products includes financial milestones for Nona Biosciences; Umoja will handle further development and commercialization.
  3. Pre-revenue clinical-stage operations: Company is clinical-stage and has not yet generated product revenue; operations are funded by equity financings (Series B $210M in 2021, Series C $100M in 2025) and strategic partner capital.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Umoja Biopharma product offering

Product offering

Core offering

Umoja Biopharma develops in vivo CAR T cell therapies using its proprietary VivoVec platform, a surface-engineered lentiviral vector delivery system that generates chimeric antigen receptor (CAR) T cells directly inside the patient's body via a single infusion. The approach eliminates the weeks-to-months-long ex vivo cell manufacturing process and the need for lymphodepleting chemotherapy, with complementary platforms (RACR, TumorTag, Engineered iPSCs) supporting in vivo cell expansion, tumor targeting, and allogeneic manufacturing.

Product overview

Umoja Biopharma is a clinical-stage biotechnology company pioneering in vivo CAR T cell therapies through an integrated platform-plus-modules architecture. The core technology platform, VivoVec, is a surface-engineered lentiviral vector delivery system that generates CAR T cells directly inside the patient's body, bypassing the complexity of ex vivo manufacturing. VivoVec is complemented by two synergistic modular platforms: the RACR (Rapamycin-Activated Cytokine Receptor) platform, which enhances survival and expansion of in vivo-engineered cells (and also drives ShRED differentiation of iPSCs), and the TumorTag platform, a portfolio of bispecific small molecule adaptors that selectively label tumor cells for recognition by universal TagCAR T cells. Together these three platforms power Umoja's pipeline of clinical and preclinical product candidates: UB-VV111 (CD19 in vivo CAR T, FDA Fast Track Designation), UB-VV400/410 (CD22 in vivo CAR T, in-licensed from IASO Biotherapeutics), UB-VV300/310 (CD20 in vivo CAR T), UB-VV500 (BCMA x GPRC5D dual-targeted in vivo CAR T for multiple myeloma), and UB-TT170 (TumorTag targeting folate receptors for osteosarcoma). The Engineered iPSCs platform provides an allogeneic, off-the-shelf manufacturing route. All in vivo CAR T candidates are manufactured at Umoja's company-owned CLIMB facility in Louisville, Colorado, the only in-house lentiviral vector manufacturing capability among in vivo CAR T cell companies. Umoja's CD19 program (UB-VV111) is out-licensed to AbbVie under an exclusive option, while UB-VV400/410 is in-licensed from IASO Biotherapeutics.

Differentiator

Problem solved

Functional benefit

Brands

  • VivoVec: Umoja's flagship proprietary in vivo gene delivery platform that enables the in vivo generation of CAR T cells within the patient's body using a lentiviral vector delivery system.
  • RACR (Rapamycin-Activated Cytokine Receptor)
  • TumorTag

Products and services

  • VivoVec Platform Surface-engineered lentiviral vector delivery platform that generates CAR T cells directly within the patient's body via a single infusion, bypassing ex vivo cell production. Features Multi-Domain Fusion (MDF) surface engineering and cocal fusion glycoprotein pseudotyping, and is modular to deliver any CAR payload against multiple surface targets. Licensed for CD19 candidates to AbbVie under exclusive option.
  • RACR (Rapamycin-Activated Cytokine Receptor) Platform Synthetic cytokine receptor system combined with VivoVec to provide enhanced survival and expansion to in vivo-generated immune cells. Activated by rapamycin (an FDA-approved drug) to provide a proliferative signal that can replace lymphodepleting chemotherapy; also enables Synthetic Receptor Enabled Differentiation (ShRED) of iPSCs.
  • TumorTag Platform Portfolio of bispecific small molecule adaptors that selectively bind tumor or tumor stromal cells and label them with fluorescein (or other tags), marking them for destruction by universal TagCAR T cells. Cocktails of TumorTags enable labeling of multiple targets to address antigen escape and tumor heterogeneity in solid tumors.
  • Engineered iPSCs Platform Induces pluripotent stem cells engineered with RACR and universal TagCAR to produce off-the-shelf, allogeneic immune effector cells (RACR-iCIL) with unlimited expansion capacity, genomic consistency, and protection against host-versus-graft rejection.
  • UB-VV111 Investigational off-the-shelf in vivo CAR T cell therapy targeting CD19 for hematologic malignancies, including relapsed/refractory Large B-cell Lymphoma and Chronic Lymphocytic Leukemia. Generates CD19-directed CAR T cells in vivo using VivoVec platform, eliminating ex vivo manufacturing and lymphodepletion. First in vivo CAR T to receive FDA IND clearance.
  • UB-VV400/410 In vivo CAR T cell therapy program targeting CD22 for the treatment of Non-Hodgkin Lymphoma and autoimmune diseases, built on the VivoVec platform. In-licensed from IASO Biotherapeutics. Phase 1 trial ongoing (NCT06743503).
  • UB-VV300/310 Preclinical in vivo CAR T cell therapy program targeting CD20, currently in IND-enabling stage of preclinical development. Built on the VivoVec platform.
  • UB-VV500 Umoja's dual-targeted BCMA x GPRC5D in vivo CAR T cell therapy program for the treatment of multiple myeloma. Described as the industry's first combination BCMA x GPRC5D in vivo CAR T cell therapy for multiple myeloma, addressing antigen escape after single-target BCMA therapy.
  • UB-TT170 Proprietary TumorTag small molecule that selectively binds to folate receptors (FR) on tumor cells, labels them with fluorescein, and marks them for destruction by anti-fluorescein CAR T cells. Initial indication in osteosarcoma (up to 80% of osteosarcoma tumor samples show FR expression). Being evaluated in the Phase 1 ENLIGHTen clinical trial at Seattle Children's.
  • CLIMB (Colorado Laboratory & Innovative Manufacturing Building) Company-owned 146,000 square-foot lentiviral vector development and manufacturing facility in Louisville, Colorado, co-located with R&D labs. Umoja is the only in vivo CAR T cell therapy company with in-house manufacturing capacity, using a suspension-based process with both transient transfection and stable producer cell line technologies to produce VivoVec-based drug products.

Quantifiable outcome

  • UB-VV111 was the first in vivo CAR T cell therapy to receive FDA IND clearance in 2024 and FDA Fast Track Designation in September 2025.
  • +4 more outcomes

Companies that use Umoja Biopharma

Customer profile

Segments4 records

Ideal customer profiles2 records

Umoja Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Umoja Biopharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and flagship.

  • Nona BiosciencesmajorStrategic or Co-development Partner · 5 November 2025Expanded collaboration to develop multiple in vivo CAR-T products using combined platforms. The agreement includes financial milestones for Nona Biosciences; Umoja will handle further development and commercialization of the resulting therapies.
  • AbbVieflagshipOEM/ Whitelabel/ Licensing Partner · 1 January 2024AbbVie holds an exclusive option to license Umoja's CD19-directed in vivo CAR T cell therapy candidates, including UB-VV111 (NCT06528301). AbbVie's existing $1.4 billion option deal is widely noted by industry analysts as a key strategic consideration for any future acquisition of Umoja.
  • Seattle Children's Research InstitutemajorImplementation/ SI/ Consulting Partner · 3 May 2022Phase 1 ENLIGHTen trial partnership for UB-TT170 TumorTag with Seattle Children's Therapeutics providing anti-fluorescein CAR T cells manufactured in their Cure Factory GMP facility. Seattle Children's also founded the underlying scientific work supporting Umoja.
  • IASO BiotherapeuticsmajorOEM/ Whitelabel/ Licensing PartnerIn-licensing partner for Umoja's CD22-directed program (UB-VV400/410) for Non-Hodgkin Lymphoma and autoimmune indications, currently in Phase 1 (NCT06743503).

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Umoja Biopharma competitors and assessment

Company assessment

Direct peers

  • Capstan Therapeutics: Capstan Therapeutics is a clinical-stage biotech developing in vivo CAR T cell therapies using lipid nanoparticle (LNP) delivery of mRNA. Directly comparable to Umoja as an in vivo CAR T peer pursuing the same core thesis of generating CAR T cells inside the patient without ex vivo manufacturing.
  • Interius BioTherapeutics: Interius was a clinical-stage in vivo CAR T company using viral vector delivery to generate CAR T cells in vivo. Acquired by Gilead/Kite for $350M, validating the in vivo CAR T category and providing a comparable benchmark for Umoja's platform approach.
  • Kelonia Therapeutics: Kelonia is an in vivo CAR T company using lentiviral vector delivery. Acquired by Eli Lilly for approximately $7B, representing the largest in vivo CAR T exit to date and a key comparable for valuing Umoja's platform.
  • Caribou Biosciences: Caribou Biosciences is a clinical-stage cell therapy company developing allogeneic CAR T cell therapies using CRISPR gene editing. Comparable to Umoja as a cell therapy platform company pursuing off-the-shelf CAR T approaches, though using ex vivo rather than in vivo manufacturing.
  • Allogene Therapeutics: Allogene Therapeutics is a clinical-stage cell therapy company developing allogeneic (off-the-shelf) CAR T cell therapies for hematologic malignancies and solid tumors. Comparable to Umoja as an off-the-shelf CAR T peer addressing the same patient access barriers, though using ex vivo allogeneic manufacturing.
  • CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene editing company developing CRISPR/Cas9-edited allogeneic CAR T cell therapies. Comparable to Umoja as a next-generation engineered cell therapy peer with active clinical CAR T programs in hematologic malignancies.

Emerging players

  • Ensoma: Ensoma is a genomics medicine company developing in vivo gene editing and cell therapy using engineered viral vectors. Comparable as an in vivo engineered cell therapy peer, though with a broader gene editing focus rather than purely CAR T.

Broad incumbents

  • Bristol Myers Squibb: Bristol Myers Squibb markets Breyanzi (liso-cel) and Abecma (ide-cel) CAR T cell therapies. Comparable to Umoja as a broad incumbent offering commercial CAR T products in the same B-cell and multiple myeloma indications Umoja is pursuing with UB-VV111 and UB-VV500.
  • Gilead Sciences (Kite): Gilead's Kite Pharma division markets Yescarta and Tecartus CAR T cell therapies for hematologic malignancies. Comparable to Umoja as a broad incumbent with active in vivo CAR T investment (Interius acquisition $350M) overlapping with Umoja's pipeline indications.
  • Novartis: Novartis markets Kymriah, the first FDA-approved CAR T cell therapy, and has active cell therapy pipeline investment. Comparable to Umoja as a broad incumbent in CAR T cell therapy commercialization, particularly relevant given AbbVie's option on Umoja's CD19 program (Kymriah's primary indication).

Market position

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Umoja Biopharma social profiles

Digital presence

Umoja Biopharma compliance and trust

Trust signal

Compliance2 records

Umoja Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Umoja Biopharma leadership team

Management profile

Number of profiles

Profiles12 records

Umoja Biopharma funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Umoja Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Umoja Biopharma

What does Umoja Biopharma do?

Umoja Biopharma develops in vivo CAR T cell therapies using its proprietary VivoVec platform, a surface-engineered lentiviral vector delivery system that generates chimeric antigen receptor (CAR) T cells directly inside the patient's body via a single infusion. The approach eliminates the weeks-to-months-long ex vivo cell manufacturing process and the need for lymphodepleting chemotherapy, with complementary platforms (RACR, TumorTag, Engineered iPSCs) supporting in vivo cell expansion, tumor targeting, and allogeneic manufacturing.

Is Umoja Biopharma a public or private company?

Umoja Biopharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Umoja Biopharma founded?

Umoja Biopharma was founded in 2019. It employs 251 to 500 people.

Where is Umoja Biopharma based?

Umoja Biopharma is headquartered in Seattle, United States, in the North America region.

How does Umoja Biopharma make money?

Three revenue lines are on record. Out-licensing option / milestone payments are the primary driver. The others are co-development milestone payments and pre-revenue clinical-stage operations.

Who are Umoja Biopharma's main competitors?

Direct peers on record are Capstan Therapeutics, Interius BioTherapeutics, Kelonia Therapeutics, Caribou Biosciences, Allogene Therapeutics and CRISPR Therapeutics. Ensoma is listed as an emerging player. Broad incumbents are Bristol Myers Squibb, Gilead Sciences (Kite) and Novartis.

Does Umoja Biopharma have an API?

No public API is recorded for Umoja Biopharma.

What industry is Umoja Biopharma in?

Umoja Biopharma's product category is In Vivo CAR T Cell Therapy. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireUmoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry’s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed/Refractory B Cell MalignanciesUmoja Biopharma announced FDA clearance of its Investigational New Drug application for UB-VV400, described as the industry's first known CD22-directed in vivo CAR T cell therapy for adults with relapsed/refractory B cell malignancies. The Phase 1/2 VIBRANT-1 study will open at U.S. clinical sites with the first patient expected to be dosed in Q3 2026, evaluating UB-VV400 in combination with rapamycin. Initial clinical data from the investigator-initiated trial of UB-VV400 in China is expected to be shared at a major medical meeting in the second half of 2026.Labiotech.euEight in vivo CAR T biotechs to follow closelyEight in vivo CAR-T biotechs are profiled, including Umoja Biopharma, Vyriad, CPTx, Legend, Strand, Alaya.bio, AAVivo, and Create Medicines. Their lead candidates target CD19, BCMA, or other antigens, with some in clinical trials. Big pharma is acquiring these companies for billions.BioWorldDual-targeting, rapamycin-enhanced CAR T for multiple myelomaUmoja Biopharma performed preclinical studies on UB-VV500, an off-the-shell lentiviral vector CAR T-cell product based on its Vivovec technology. The product is designed to engineer fully human anti-BCMA/GPRC5D dual-targeting CAR T cells for potential treatment of multiple myeloma.Labiotech.euIn vivo CAR-T gains momentum as big pharma bets billionsBig pharma is shifting toward in vivo CAR-T therapies, with Lilly planning a $7B acquisition of Kelonia Therapeutics. Other deals include AstraZeneca's $1B purchase of EsoBiotec and Gilead's $350M buy of Interius BioTherapeutics. The shift aims to overcome manufacturing and cost barriers of ex vivo CAR-T.GlobeNewswireUmoja Biopharma Announces Unveiling of UB-VV500 in Upcoming Poster Presentation at the American Society of Gene & Cell Therapy Annual MeetingUmoja Biopharma announced that preclinical data for UB-VV500, its dual-targeted BCMA x GPRC5D in vivo CAR T cell therapy for multiple myeloma, will be presented at the American Society of Gene & Cell Therapy Annual Meeting on May 13, 2026. The company expects to advance UB-VV500 into a Phase 1 clinical trial by the end of 2026, building on positive early clinical results from its existing VivoVec platform-based programs. Dual-targeting represents an emerging strategy in multiple myeloma immunotherapy as patients progress beyond existing BCMA-directed therapies.FierceBiotechAfter Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?Eli Lilly announced a $7 billion deal to acquire Kelonia Therapeutics, marking the pharma's second major bet on in vivo CAR-T this year after buying Orna Therapeutics for up to $2.4 billion in February. Industry analyst Ben Zercher predicts in vivo CAR-T dealmaking will slow due to a shortage of viable targets, identifying Umoja Biopharma as one of the few remaining independent companies with clinical-stage candidates, though AbbVie's existing $1.4 billion option deal could complicate any acquisition. Kelonia's board member Bryan Roberts recounted that the company nearly ran out of cash before positive first-in-human data from a phase 1 trial presented at an American Society of Hematology conference turned investor sentiment, ultimately justifying Lilly's $3.25 billion upfront payment with potential milestones reaching $7 billion.GlobeNewswireUmoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of DirectorsUmoja Biopharma announced the appointment of Dr. Marcela Maus and Dr. Athena Countouriotis to its Board of Directors. Dr. Maus is a prominent translational physician-scientist in T cell-based cancer therapies at Massachusetts General Hospital and Harvard Medical School, while Dr. Countouriotis is the CEO of Avenzo Therapeutics and previously led Turning Point Therapeutics through its 2022 acquisition. The company stated the appointments will support advancement of its VivoVec in vivo gene delivery platform and clinical programs for CAR T therapies targeting cancer and autoimmune diseases.PhirdaMNC 超百亿美元卡位的体内 CAR-T 有哪些新期待?Major pharmaceutical companies have spent over $10 billion on in vivo CAR-T platforms, with clinical data emerging in 2025. LNP-based therapies target autoimmune diseases, while lentiviral approaches focus on tumors, with several candidates entering clinical trials.BioSpaceNona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell TherapiesNona Biosciences announced an expanded evaluation and license agreement with Umoja Biopharma to develop multiple in vivo CAR-T cell therapies, building on a collaboration established in September 2024. The partnership combines Nona's proprietary antibody platforms (HCAb Harbour Mice® and NonaCarFx™) with Umoja's VivoVec™ platform, with Nona eligible to receive upfront, option exercise, and milestone payments while Umoja leads development and commercialization. The companies aim to advance next-generation in vivo CAR-T therapies for oncology and autoimmunity that could transform patient access and care.